Weight and plasma biochemistry. by Søren Egstrand (10906087)

“…<div><p>Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. …”

White-to-opaque switching frequencies of single TF heterozygotes in a <i>WOR1</i>(KR-to-G) strain background. by Collin Ganser (8924843)

“…Colored bars indicate significant differences from the WT control; blue for decreased switching and red for increased switching. …”

Table 1_The association between a dietary index for the gut microbiota and frailty in older adults: emphasising the mediating role of inflammatory indicators.docx by Huangyi Yin (18593848)

“…After adjusting for all of the covariates, each unit increase in the DI-GM was associated with a 6% decrease in the prevalence of frailty (OR = 0.94; 95% CI: 0.89, 0.99; p = 0.020). …”

Data Sheet 1_Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.pdf by Tina Bartosik (12300785)

“…During 24 weeks of dupilumab therapy, there were no major changes in microbiome diversity or composition observed (Shannon index: V1-V4:p-adj=0.25, Chao 1 Index V1-V4:p-adj=0.31), and only 2 out of 8 patients showed a decrease in staphylococci abundance.…”

Table 3_A scoping review of the feasibility, usability, and efficacy of digital interventions in older adults concerning physical activity and/or exercise.docx by Ethan C. J. Berry (21074345)

“…Background:<p>The global population is aging, leading to significant health challenges among older adults, such as reduced muscle mass, increased risks of dementias, and chronic diseases. …”

Table 1_A scoping review of the feasibility, usability, and efficacy of digital interventions in older adults concerning physical activity and/or exercise.xlsx by Ethan C. J. Berry (21074345)

“…Background:<p>The global population is aging, leading to significant health challenges among older adults, such as reduced muscle mass, increased risks of dementias, and chronic diseases. …”

DataSheet1_Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis.docx by K. Melissa Hallow (9248960)

“…The drug concentration required to cause a decrease in [ET1-ET_B] was lower as ET_A selectivity decreased.…”

Table 2_A scoping review of the feasibility, usability, and efficacy of digital interventions in older adults concerning physical activity and/or exercise.docx by Ethan C. J. Berry (21074345)

“…Background:<p>The global population is aging, leading to significant health challenges among older adults, such as reduced muscle mass, increased risks of dementias, and chronic diseases. …”

Table_1_Causal relationship between non-alcoholic fatty liver disease and sarcopenia: a bidirectional Mendelian randomization study.DOCX by Meng Chen (48769)

“…In the reverse MR study, weight median analysis showed that NAFLD caused a decrease in ALM (OR = 0.953, 95%CI 0.957–0.994, p = 0.001); whereas NAFLD showed no correlation with usual walking pace or grip strength (all with p > 0.05). …”

Fibroblast growth factor 18 stimulates chondrocyte proliferation by modulating FOXN2 to mitigate post-traumatic osteoarthritis in a mouse model by Gao Xi (22574101)

“…Intriguingly, FOXN2 expression was significantly upregulated in FGF18-knockout chondrocytes but restored upon FGF18 overexpression, identifying FOXN2 as a downstream mediator of FGF18 in PTOA pathophysiology. …”

Image 1_Exogenous prostaglandin D2 as a modulator in bovine endometritis: implications for reducing antibiotic use in dairy cattle.pdf by Xiaolin Yang (276496)

“…Introduction<p>Bovine endometritis is a common postpartum uterine infection that significantly impacts the health and production performance of dairy cows, leading to economic losses for farms. …”

Data Sheet 1_Acute effect of endurance exercise on human milk insulin concentrations: a randomised cross-over study.pdf by Rebecca Lyng Holm (20620406)

“…There was no statistically significant effect of exercise on insulin concentration, but a tendency of reduced concentrations 4 h after HIIT (p = 0.093). …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”